White Teresa, Larson Heidi, Minnella Alexandra, Hochster Howard S
Yale University.
Yale New Haven Hospital.
Clin J Oncol Nurs. 2017 Apr 1;21(2):E30-E37. doi: 10.1188/17.CJON.E30-E37.
BACKGROUND: Treatment-related adverse events (AEs) are common in patients with metastatic colorectal cancer (mCRC) receiving chemotherapy. These AEs may affect patient adherence, particularly with completely oral regimens, such as trifluridine/tipiracil (TAS-102, Lonsurf®), an antimetabolite agent for patients with mCRC refractory or intolerant to standard therapies. .
OBJECTIVES: This article reviews strategies for promoting adherence and educating patients and caregivers about oral therapy with trifluridine/tipiracil. .
METHODS: Recommended strategies for managing AEs are reviewed, with a focus on the most common AEs reported in patients with mCRC receiving trifluridine/tipiracil in clinical trials. .
Oncology nurses play an important role in educating and counseling patients regarding treatment and its potential side effects. Among patients with mCRC refractory or intolerant to standard therapies, trifluridine/tipiracil was found to have a favorable safety profile. It is associated with hematologic AEs as well as a low incidence of nausea, diarrhea, vomiting, anorexia, and fatigue.
在接受化疗的转移性结直肠癌（mCRC）患者中，与治疗相关的不良事件（AE）很常见。这些不良事件可能会影响患者的依从性，尤其是对于完全口服的治疗方案，如曲氟尿苷/替匹嘧啶（TAS-102，朗斯弗®），一种用于对标准疗法难治或不耐受的mCRC患者的抗代谢药物。
本文综述了促进依从性以及对患者和护理人员进行曲氟尿苷/替匹嘧啶口服治疗教育的策略。
对管理不良事件的推荐策略进行综述，重点关注在临床试验中接受曲氟尿苷/替匹嘧啶治疗的mCRC患者报告的最常见不良事件。
肿瘤学护士在对患者进行治疗及其潜在副作用的教育和咨询方面发挥着重要作用。在对标准疗法难治或不耐受的mCRC患者中，发现曲氟尿苷/替匹嘧啶具有良好的安全性。它与血液学不良事件以及低发生率的恶心、腹泻、呕吐、厌食和疲劳有关。
